HELIOFLUX
OperatingHelioFlux, Inc.
Healthcare · Raleigh, NC · Founded 2023
Using quantum mechanics, biophysics and artificial intelligence to reprogram disease
Financials
FY2022–FY2024 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps markedA dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Team
5 people
Dr. Nirosha Murugan's pioneering cancer research explores cellular communication, tissue mispatterning, and cancer treatment. As a Tier II Canada Research Chair in Tissue Biophysics, her work at HelioFlux holds promise for revolutionizing oncology.
Kelly Lucas, a dynamic entrepreneur with a strong background in science and business, co-founded HelioFlux with a clear vision: to merge cutting-edge science with practical application. Her experience at the intersection of quantum biology and business strategy makes her an invaluable asset in driving HelioFlux towards new horizons in cancer care. Kelly was an Honors Graduate of the University of North Carolina in Chapel Hill and received her MBA from The Kelley School of Business.
Jim, an accomplished venture investor, focuses on retail and ecommerce tech at Composite Ventures. With notable early investments in PayPal and successful exits to major companies like Cisco, he's recognized on Forbes' "Midas List" multiple times. Co-founder of March Capital and Clearstone Venture Partners, Jim began his career at Austin Ventures in 1995.
With a deep understanding of the biotech industry and a knack for connecting scientific innovation with market needs, Glenn Lucas plays a crucial role in HelioFlux's business development strategy. His expertise ensures that our groundbreaking technology reaches its full potential in transforming cancer treatment.
Names and titles as disclosed on StartEngine, SEC Form C. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 1 of 2 annual reports (FY2024–FY2025)
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.